GSKD Stock Overview
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£8.80 |
| 52 Week High | UK£12.00 |
| 52 Week Low | UK£8.75 |
| Beta | 0.33 |
| 11 Month Change | -17.76% |
| 3 Month Change | n/a |
| 1 Year Change | -1.12% |
| 33 Year Change | -23.48% |
| 5 Year Change | n/a |
| Change since IPO | -98.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSKD | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | -17.8% | -1.3% | 7.6% |
| 1Y | -1.1% | -19.3% | 120.6% |
Return vs Industry: GSKD exceeded the AR Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: GSKD underperformed the AR Market which returned 121.8% over the past year.
Price Volatility
| GSKD volatility | |
|---|---|
| GSKD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in AR Market | 7.2% |
| 10% least volatile stocks in AR Market | 4.3% |
Stable Share Price: GSKD's share price has been volatile over the past 3 months compared to the AR market.
Volatility Over Time: Insufficient data to determine GSKD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GSKD fundamental statistics | |
|---|---|
| Market cap | US$68.62b |
| Earnings (TTM) | US$3.15b |
| Revenue (TTM) | US$39.23b |
21.8x
P/E Ratio1.7x
P/S RatioIs GSKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSKD income statement (TTM) | |
|---|---|
| Revenue | UK£31.31b |
| Cost of Revenue | UK£8.65b |
| Gross Profit | UK£22.67b |
| Other Expenses | UK£20.15b |
| Earnings | UK£2.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 72.39% |
| Net Profit Margin | 8.02% |
| Debt/Equity Ratio | 119.4% |
How did GSKD perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield99%
Payout RatioDoes GSKD pay a reliable dividends?
See GSKD dividend history and benchmarks| GSK dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Jan 09 2025 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 45 days |
Does GSKD pay a reliable dividends?
See GSKD dividend history and benchmarks